Oncolytic Virus (rHSV) Pipeline
Pipeline
Developing Products That are
Potent, Enabling, Novel and Safe
Potent, Enabling, Novel and Safe
-
Product
Indication
Drug
DiscoveryPre-clinical
IND
Phase I
Phase II
Phase III
BLA
Commer-cialization
-
MVR-T3011 IP
MVR-T3011 IP
MVR-T3011 IP
MVR-T3011 IP Combo PD-1
MVR-T3011 IT
MVR-T3011 IT Combo PD-1
MVR-T3011 IT
MVR-T3011 IV
MVR-C5252
Bladder Cancer, BCG-unresponsive NMIBC (Papillary and CIS)
Bladder Cancer, BCG-unresponsive NMIBC (Papillary and CIS)
Bladder Cancer, BCG-naive NMIBC (Papillary and CIS)
Bladder Cancer, MIBC
HNSCC and other Solid Tumors
HNSCC and other Solid Tumors
HNSCC and other Solid Tumors
Solid Tumors
Glioma
FDA (Global MRCT), Phase ll (NCT06971614)NMPA, Phase I/IIT (NCT06427291)<sup style=" transform: translateY(-5px); ">1</sup>NMPA, IITNMPA, IITFDA, Phase I/lla (NCT04370587), Fast Track Designation<sup style=" transform: translateY(-5px); ">2</sup>FDA, Phase I/lla (NCT04370587)NMPA, Phase I/lla (NCT05602792)FDA, Phase I/IIa (NCT04780217）FDA, Phase I/IIT (NCT06126744), Orphan Drug Designation<sup style=" transform: translateY(-5px); ">3</sup>
-
Various Administration
Methods
Intravenous
Intratumoral
Intraperitoneal,
intrapleural,
intravesical
Multi-regional Clinical Trials
Clinical trials are the research studies intended to find out if a new treatment is safe and provides better outcomes than the existing standard of care–the best available known treatment. You can find more information about our ongoing clinical trials below.
Biomarker
Biomarker kit to assess the efficacy of OV products and pre-screen potential patients for oHSV clinical treatment
-
Platform
Product
R&D/Pilot test/Manufacturing
Drug Quality Control
Clinical Trials
Registration
Approval
-
Biomarker Program
Biomarker Kit
